Genentechs Rituxan Has Generated Strong Growth in the NHL Market since Its Launch, Although Rituxans Market Penetration May Have Peaked - New Approaches To The Treatment Of Non-Hodgkins Lymphoma.
M2 PRESSWIRE-19 December 2006-Research and Markets: Genentechs Rituxan Has Generated Strong Growth in the NHL Market since Its Launch, Although Rituxans Market Penetration May Have Peaked - New Approaches To The Treatment Of Non-Hodgkins Lymphoma(C)1994-2006 M2 COMMUNICATIONS LTD RDATE:21122006
Total Revenue for drugs treating non-Hodgkins lymphoma expected to grow to $4.7 billion by 2008.
M2 PRESSWIRE-23 December 2003-Research and Markets: Total Revenue for drugs treating non-Hodgkins lymphoma expected to grow to $4.7 billion by 2008.(C)1994-2003 M2 COMMUNICATIONS LTD RDATE:12232003 Research and Markets announces the addition of this exciting new report entitled Patterns and Trends
Primary renal non-Hodgkins lymphoma presenting with acute renal failure
Primary renal lymphoma (PRL) has been reported in medical literature. Its occurrence is rare and controversial, the kidney being an extranodal organ. We report a case of primary renal lymphoma presenting with acute-on-chronic renal failure and unilateral involvement of the left kidney without
Coulter Corporation and InterWest Partners form company to market new treatment for non-Hodgkins lymphoma.
PALO ALTO, CalifBUSINESS WIREMarch 27, 1995-Coulter Corporation and InterWest Partners announced they are forming a pharmaceutical company to market a promising new treatment for non-Hodgkins lymphoma. The company, called Coulter Pharmaceutical, Inc., will be headquartered in Palo Alto, Calif. Its
Vegetables reduce risk of non-Hodgkins lymphomas.
Non-Hodgkins lymphomas are cancers of the lymph nodes, spleen, and other components of the immune system. The incidence of non-Hodgkins lymphomas has increased over the past 25 years for unknown reasons. This type of cancer accounts for about 4 percent of all new cancer diagnoses and 3 percent of
NON-HODGKINS LYMPHOMA
00-00-0000 THIS IS A RUSH TRANSCRIPT. THIS COPY MAY NOT BE IN ITS FINAL FORM AND MAY BE UPDATED. CHARLES GIBSON: King Hussein died of non-Hodgkins lymphoma, and not many of us know what that is. So our medical editor, Dr. Tim Johnson is joining us from Boston to tell us more about it. Tim, good to
Tumor Cell Purging by High Density Microparticles Shows Favorable Phase I/II Results in Patients With Non-Hodgkins Lymphoma.
NEW ORLEANS, Dec. 6 /PRNewswire/ - Eligix, Inc. announced today the results of the first human clinical trial using a novel tumor cell purging technology that has promise for the treatment of patients suffering from B- cell malignancies such as non-Hodgkins lymphoma, who undergo bone marrow stem
FDA approves first radiopharmaceutical product to treat non-Hodgkins Lymphoma.
M2 PRESSWIRE-20 February 2002-US FDA: FDA approves first radiopharmaceutical product to treat non-Hodgkins Lymphoma (C)1994-2002 M2 COMMUNICATIONS LTD RDATE:20022002 FDA today approved a novel treatment regime for one type of non-Hodgkins Lymphoma (NHL) that for the first time includes a monoclonal
Research and Markets : Stakeholder Opinions: Non-Hodgkins Lymphoma - Immunotherapy Stimulates the Market.
DUBLIN, Ireland - Research and Markets (httpwww.researchandmarkets.com/reports/c9969) has announced the addition of Stakeholder Opinions: Non-Hodgkins Lymphoma - Immunotherapy Stimulates the Market to their offering Introduction The disproportionate rise in non-Hodgkins Lymphoma (NHL) incidence
Successful drug developed for non-Hodgkins lymphoma
JUDY SIEGEL Jerusalem Post 12-20-2000 Headline: Successful drug developed for non-Hodgkins lymphoma Byline: JUDY SIEGEL Edition; Daily Section: News Page: 05 Wednesday, December 20, 2000 - A drug developed by a California oncologist who spent more than a year at the Weizmann Institute in Rehovot
